. 2025 Feb 5;9:695. Originally published 2024 Nov 27. [Version 2] doi: 10.12688/wellcomeopenres.22498.2

Table 3. Primary non-inferiority analysis for null hypothesis HR ≤ 0.75; All-cause mortality or new neurological event until 12 months after randomisation.

	All-cause mortality or new neurological event		Hazard ratio (CI) *
	Dexamethasone	Placebo	Hazard ratio (CI) *
All patients of CT or CC genotype	XX/XX	XX/XX	X.XX (X.XX, X.XX)
All patients of CC genotype	XX/XX	XX/XX	X.XX (X.XX-X.XX)

* CI=confidence interval. Significance level will be based on the Spiessens and Debois method

XX/XX denotes the number of participants experiencing the event divided by the total number of participants in the treatment arm